Benzinga | Jul 13, 2020 02:42PM EDT

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $12

Needham maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $18 to $12.